Экспериментальные модели в изучении патогенеза и разработке методов лечения рака яичников (систематический обзор):

Городнова Т.В., Соколенко А.П., Кулигина Е.Ш. и др. Особенности рецидивирования распространенного BCRA-позитивного рака яичников // Вопросы онкологии. 2017;63(2):298–303 [Gorodnova T.V., Sokolenko A.P., Kuligina E.Sh. et al. Features of recurrence of BCRA-positive ovarian cancer // Problems in oncology. 2017;63(2):298–303. In Russ.].

Румянцев А.А., Тюляндина А.С., Покатаев И.А., Тюляндин С.А. Спорные вопросы оптимальной тактики хирургического лечения больных распространенным раком яичников // Злокачественные опухоли. 2017;7(3):13–22. https: // doi: 10.18027 / 2224–5057–2017–7–3–13–22 [Rumyantsev A.A., Tjulandina A.S., Pokataev I.A., Tjulandin S.A. Controversies in surgical treatment of advanced ovarian cancer // Malignant Tumours. 2017;7(3):13–22. https: // doi: 10.18027 / 2224–5057–2017–7–3–13–22 (In Russ.)].

Mihanfar A, Fattahi A, Nejabati HR. MicroRNA-mediated drug resistance in ovarian cancer // J Cell Physiol. 2019;234(4):3180–3191. https: // doi: 10.1002/jcp.26060

Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack M.S. Epithelial Ovarian Cancer Experimental Models // Oncogene. 2014 Jul 10;33(28):3619–3633. https: // doi: 10.1038/onc.2013.321

Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy // Cancer Chemother. Pharmacol. 2018;81(1):17–38. https: // doi: 10.1007/s00280-017-3501-8

Виллерт А.Б., Коломиец Л.А., Юнусова Н.В., Фесик Е.А. Молекулярно-генетические подтипы рака яичников: перспективы дальнейших исследований // Вопросы онкологии. 2019;65(1):56–62 [Villert A.B., Kolomiets L.A., Unusova N.V., Fesik E.A. Molecular and genetic subtypes of ovarian cancer: prospects for further studies // Problems in oncology. 2019; 65(1): 56–62 (In Russ.)].

Горошинская И.А., Сурикова Е.И., Шалашная Е.В. и др. Cостояние свободнорадикальных процессов при раке яичников с разной распространенностью и течением заболевания. Известия высших учебных заведений // Северо-Кавказский регион. Серия: естественные науки. 2017;(4–2):10–19. https: // doi: 10.23683/0321-3005-2017-4-2-10-19 [Goroshinskaya I.A., Surikova E.I, Shalashnaya E.V. et al. State of free radical processes in ovarian cancer with different prevalence and course of the disease. Izvestiya vuzov // Severo-Kavkazskii Region. Natural Science. 2017;(4–2): 10–19 . https: // doi: 10.23683/0321-3005-2017-4-2-10-19 (In Russ.)].

Maru Y, Hippo Y. Current Status of Patient-Derived Ovarian Cancer Models // Cells. 2019;8(5):505. https: // doi: 10.3390/cells8050505.

Cybulska P, Stewart JM, Sayad A et al. A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing // Am. J. Pathol. 2018;188(5):1120–11. https: // doi: 10.1016/j.ajpath.2018.01.019

Damia G, Broggini M. Platinum Resistance in Ovarian Cancer: Role of DNA Repair // Cancers 2019, 11(1):119. https: // doi: 10.3390/cancers11010119

Rosales-Nieves AE, Gonzalez-Reyes A. Genetics and mechanisms of ovarian cancer: Parallels between Drosophila and humans // Semin. Cell Dev. Biol. 2014;28:104–109. https: // doi: 10.1016/j.semcdb.2014.03.031

Tudrej P, Kujawa KA, Cortez AJ, Lisowska KM. Characteristics of in Vivo Model Systems for Ovarian Cancer Studies // Diagnostics (Basel). 2019;9(3):120. https: // doi: 10.3390/diagnostics9030120

Hardwick LJA, Philpott A. Xenopus Models of Cancer: Expanding the Oncologist's Toolbox. Front Physiol. 2018;9:1660. doi: 10.3389/fphys.2018.01660

Barua A, Bitterman P, Abramowicz JS et al. Histopathology of ovarian tumors in laying hens a preclinical model of human ovarian cancer // Int. J. Gynecol. Cancer. 2009;19(4):531–539. https: // doi: 10.1111/IGC.0b013e3181a41613

Bernardo AM, Thorsteinsdottir S, Mummery CL. Advantages of the avian model for human ovarian cancer // Mol. Clin. Oncol. 2015;3(6):1191–1198. https: // doi: 10.3892/mco.2015.619

Ribatti D. The chick embryo chorioallantoic membrane (CAM). A multifaceted experi-mental model // Mech. Dev. 2016;141:70–77. https: // doi: 10.1016/j.mod.2016.05.003. Трад. Мод. 1 Синг.

Daniel D. Development. ID8: A syngeneic mouse model for testing ovarian cancer immunotherapies. 07.11.2017. The site of Covance. Available at https: // www.covance.com/industry-solutions/oncology/preclinical/tumor-spotlights/id8-syngeneic-mouse-model-testing-ovarian-cancer-immunotherapies.html 10.06.2020. Accessed 10.09.2020.

Fan L, Liu Y, Zhang X et al. Establishment of Fischer 344 rat model of ovarian cancer with lymphatic metastasis // Arch Gynecol Obstet. 2014;289(1):149–154. https: // doi: 10.1007/s00404-013-2937-2

Беспалов В.Г., Вышинская Е.А., Васильева И.Н. и др. Повышение эффективности лечения канцероматоза брюшной полости с помощью интраперитонеальной полихимиотерапии на модели диссеминированного рака яичника // Вопросы онкологии. 2018;64(3):440‒444 [Bespalov V.G., Vyshinskaya E.A., Vasilyeva I.N. et al. Improvement of efficiency of treatment of abdominal canceromatosis by intraperitoneal polychemotherapy on model of disseminated ovarian cancer // Problems in oncology. 2018; 64(3):440‒444 (In Russ.)].

Sawyer TW, Koevary JW, Rice PFS, Barton JK. In Vivo Optical Coherence Tomography of a Mouse Model of Spontaneous Ovarian Cancer. In “Clinical and Preclinical Optical Diagnostics» II, Vol. EB101 of SPIE Proceedings (Optical Society of America, 2019), paper 11073_49. Available at https: // www.osapublishing.org/abstract.cfm?URI=ECBO-2019-11073_4. Accessed 19.08.2020

House CD, Hernandez L, Annunziata CM. Recent technological advances in using mouse models to study ovarian cancer // Front. Oncol. 2014;4:26. https: // doi: 10.3389/fonc.2014.00026

Погосянц Е.Е., Пригожина Е.Л., Еголина Н.А. Перевиваемая опухоль яичника крысы // Вопросы онкологии. 1962;11:29–36 [Pogosyants Ye.Ye., Prigozhina Ye.L., Yegolina N.A. Transplanted ovarian rat tumor // Problems in Oncology. 1962; 11:29–36 (In Russ.)].

Киреева Г.С., Беляева О.А., Сенчик К.Ю. и др. Асцитная опухоль яичников у крыс — адекватная доклиническая модель канцероматоза для изучения интраперитонеального химиоперфузионного лечения. Современное состояние вопроса // Сибирский онкологический журнал. 2019;18(1):71–78. https: // doi: 10.21294/1814-4861-2019-18-1-71-78 [Kireeva G.S., Belyaeva O.A., Senchik K.Y., Bespalov V.G., Stukov A.N., Gubareva E.A., Maydin M.A. Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment // Siberian Journal of Oncology. 2019;18 (1):71–78. https: // doi: 10.21294/1814-4861-2019-18-1-71-78 (In Russ.].

Cai Q, Yan L, Xu Y. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells // Oncogene. 2015;34(25):3315–3324. https: // doi: 10.1038/onc.2014.264

McCloskey CW, Goldberg RL, Carter LE et al. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population // Front. Oncol. 2014;4:53. https: // doi: 10.3389/fonc.2014.00053

Kuhn E, Tisato V, Rimondi E, Secchiero P. Current Preclinical Models of Ovarian Cancer // J Carcinog Mutagen 2015, 6(2):1-9. https: // doi: 10.4172/2157-2518.1000220

Gargiulo G. Next-Generation in vivo Modeling of Human Cancers. Review article // Front. Oncol. 2018;8:429. https: // doi: 10.3389/fonc.2018.00429

Mullany LK, Richards JS. Minireview: Animal Models and Mechanisms of Ovarian Cancer Development // Endocrinology. 2012;153(4):1585–1592. https: // doi: 10.1210/en.2011-2121

Harlan B, Nikitin AYu. A Quest for Better Mouse Models of Breast and Ovarian Cancers // EBioMedicine. 2015;2(10):1268–1269. https: // doi: 10.1016/j.ebiom.2015.09.017

Flesken-Nikitin A, Hwang C-I, Cheng C-Y et al. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche // Nature. 2013;495(7440):241–245. https: // doi: 10.1038/nature11979

Kim J, Coey DM, Creighton CJ et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model // Proc. Natl. Acad. Sci. USA. 2012;109:3921–3926. https: // doi: 10.1073/pnas.1117135109

Purnell BA. Modeling Ovarian Cancer // Science. 2012;335(6074):1280–1281. https: // doi: 10.1126/science.335.6074.1280-d

Perets R, Wyant GA, Muto KW et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in BRCA, Tp53, Pten models // Cancer Cell 2013, 24(6):751–765. https: // doi: 10.1016/j.ccr.2013.10.013

Fong MY, Kakar SS. Ovarian cancer mouse models: a summary of current models and their limitations // J Ovarian Res. 2009;2(1):12. https: // doi: 10.1186/1757-2215-2-12

Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to «Nude» mice // Acta Pathol Microbiol Scand. 1969;77(4):758–760. https: // doi: 10.1111/j.1699-0463.1969.tb04520.x

Szadvari I, Krizanova O, Babula P. Athymic nude mice as an experimental model for cancer treatment // Physiol. Res. 2016;65 (4):441–453. https: // doi: 10.33549/physiolres.933526

De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized Mice for the Study of Immuno-Oncology // Trends in Immunology. 2018;39(9):748–63. https: // doi: 10.1016/j.it.2018.07.00

Кит О.И., Жукова Г.В., Максимов А.Ю. и др. Ортотопические ксенографты глиальных опухолей человека: история, технологии, достижения и проблемы // Медицинский вестник Северного Кавказа. 2020;15(1):133–139. https: // doi: 10.14300/mnnc.2020.15034 [Kit O.I., Zhukova GV., Maximov A.Yu. et al. Orthotopic grafts of human malignant gliomas: history, technologies, achievements and problems // Medical News of North Caucasus. 2020;15(1):133–139. https: // doi: 10.14300/mnnc.2020.15034] (In Russ.)].

Балдуева И.А., Данилова А.Б., Нехаева Т.Л., Беляев А.М. Клеточная линия рака яичника человека 533 OOS. Патент на изобретение RU 2650759 C1, 17.04.2018. Заявка № 2017126922 от 26.07.2017 [Baldueva I.A., Danilova A.B., Nekhaeva T.L., Belyaev A.M. Human ovarian cancer cell line 533 OOS. Invention patent. RU 2650759 C1, 17.04.2018]. (in Russ.)].

Генетические и биологические коллекции Российской Федерации. Российская коллекция клеточных культур позвоночных. https: // doi: www.sevin.ru/collections/cellcolls/rcccm.html. Accessed 07.09.2020 [Geneticheskie i biologicheskie kollektsii Rossiiskoi Federatsii. Rossiiskaia kollektsiia kletochnykh kultur pozvonochnykh. Genetic and biological collections of the Russian Federation. Russian collection of vertebrate cell cultures]. (in Russ.). https: // doi: www.sevin.ru/collections/cellcolls/rcccm.html . Accessed 07.09.2020].

Letourneau IJ, Quinn MC, Wang LL et al. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer // BMC Cancer. 2012;12:379. https: // doi: 10.1186/1471-2407-12-37912, 379

Tudrej P, Kujawa KA, Cortez AJ, Lisowska KM. Characteristics of in vitro model systems for ovarian cancer studies // Oncol. Clin. Pract. 2019;15(5):246–259. https: // doi: 10.5603/OCP.2019.0024.

Tudrej P, Olbryt M, Zembala-Nozynska E et al. Establishment and characterization of the novel high-grade serous ovarian cancer cell line OVPA8 // Int. J. Mol. Sci. 2018;19(7):1–26. https: // doi: 10.3390/ijms19072080

Guo J, Cai J, Zhang Y et al. Estalishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study // International Journal of Oncology. 2017;1199–1208. https: // doi: 10.3892/ijo.2017.411

Kiguchi K, Kubota T, Aoki D et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer // Clin. Exp. Metastasis. 1998;16:751–756. 1998. https: // doi: 10.1023/A:1006537013317

Cordero AB, Kwon Y, Hua X, Godwin AK. In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer // J. Vis. Exp. 2010;42:e2125. https: // doi: 10.3791/2125

Magnotti E, Marasco WA. The latest animal models of ovarian cancer for novel drug discovery // Expert. Opin. Drug Discov. 2018;13:249–257. https: // doi: 10.1080/17460441.2018.1426567

Hernandez L, Kim MK, Lyle LT et al. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies // Gynecol. Oncol. 2016;142(2):332–340. https: // doi: 10.1016/j.ygyno.2016.05

Zhao Ya, Cao J, Melamed A et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma // PNAS. 2019;116 (6):2210–2219. https: // doi: 10.1073/pnas.1818357116

Hasan N, Ohman AW, Dinulescu DM. The promise and challenge of ovarian cancer models // Transl Cancer Res. 2015;4(1):14–28. https: // doi: 10.3978/j.issn.2218-676X.2015.01.02

Dobbin ZC, Katre AA, Steg AD et al. Using Heterogeneity of the Patient-Derived Xenograft Model to Identify the Chemoresistant Population in Ovarian Cancer // Oncotarget. 2014;5(18):8750–64. https: // doi: 10.18632/oncotarget.2373

Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens // Anticancer Res. 1993;13(2):283–286.

Bogden AE, Haskell PM, LePage DJ et al. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice // Exp Cell Biol. 1979;47(4):281–93. https: // doi: 10.1159/000162947

Maeda K, Ushijima H, Shimamoto T et al. Clinical application of subrenal capsule assay in ovarian cancer // Nihon Sanka Fujinka Gakkai zasshi. 1989;41(12):1896–1902. Japanese.

Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression // Genes Dev. 2018;32(19–20):1267–1284. https: // doi: 10.1101/gad.314617.118

Bankert RB, Balu-Iyer SV, Odunsi K et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis // PLoS ONE. 2011, 6(9):e24420. https: // doi: 10.1371/journal.pone.0024420

Fu SH, Wang J, Sun W et al. Preclinical humanized mouse model with ectopic ovarian tissues // Experimental and Therapeutic Medicine. 2014;8(3):742–746. https: // doi: 10.3892/etm.2014.1819

Непомнящих Т.С., Гаврилова Е.В., Максютов Р.А. Некоторые аспекты использования алло- и ксенографтных моделей при разработке противораковых вакцин и онколитических вирусов // Медицинская иммунология. 2019, 21(2):221–230. https: // doi: 10.15789/1563-0625-2019-2-221-230 [Nepomnyashchikh T.S., Gavrilova E.V., Maksyutov RA. Some applications of allo- and xenograft models for developing novel anticancer vaccines and oncolytic viruses // Medical Immunology (Russia). 2019;21(2):221–230. https: // doi: 10.15789/1563-0625-2019-2-221-230 (In Russ.)].

Villacorta-Martin C, Craig AJ, Villanueva A. Divergent evolutionary trajectories in transplanted tumor models // Nat Genet. 2017;49(11):1565–1566. https: // doi: 10.1038/ng.3983. PMID: 29074950

Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities // Nat Rev Cancer. 2019;19:97–109. https: // doi: 10.1038/s41568-018-0095

Maniati E, Berlato C, Gopinathan G et al. Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment // Cell Rep. 2020;30(2):525–540.e7. https: // doi: 10.1016/j.celrep.2019.12.034

White EA, Kenny HA, Lengyel E. Three-dimensional modeling of ovarian cancer // Adv. Drug. Deliv. Rev. 2014;79–80:184–192. https: // doi: 10.1016/j.addr.2014.07.003

Prina-Mello A, Jain N, Liu B et al. Culturing substrates influence the morphological, mechanical and biochemical features of lung adenocarcinoma cells cultured in 2D or 3D // Tissue Cell. 2018;50:15–30. https: // doi: 10.1016/j.tice.2017.11.003

Tzanakakis GN, Giatagana EM, Kuskov A, Nikitovic D. Proteoglycans in the Pathogenesis of Hormone- Dependent Cancers: Mediators and Effectors // Cancers. 2020;12(9). https: // doi: 10.3390/cancers12092401

Просекина Е.А., Данилова А.Б., Нехаева Т.Л., Балдуева И.А. Создание трёхмерных клеточных моделей для решения теоретических и практических задач современной онкологии // Вопросы онкологии. 2019;65(5):629–637 [Prosekina E.A., Danilova A.B., Nehaeva TL, Baldueva I.A. The creating of three-dimensional cellular models to solve theoretical and practical problems of modern oncology // Problems in oncology. 2019;65(5):629–637 (In Russ.)].

Watters KM, Bajwa P, Kenny HA. Organotypic 3D Models of the Ovarian Cancer Tumor Microenvironment // Cancers. 2018;10(8):265–274. https: // doi: org/10.3390/cancers10080265

Lu M, Henry CE, Lai H, Khine YY et al. A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles // Biomater Sci. 2019;7(4):1652–1660. https: // doi: 10.1039/c8bm01326h

Полозников А.А., Никулин С.В., Болотина Л.В. и др. Сравнение 2d- и 3d-культур аденокарциномы прямой кишки как моделей для тестирования лекарственных препаратов // Известия Академии наук. Серия химическая. 2019;12:2377–2380 [Poloznikov A.A., Alexeev BY, Nikulin SV. et al.Comparison of 2d and 3d cell cultures of colorectal adenocarcinoma as models for drug screening // Russian chemical bulletin. 2019;68(12):2377–2380 (InRuss.)].

Kopper O, de Witte CJ, Lõhmussaar K et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity // Nat Med. 2019;25(5):m838–849. https: // doi: 10.1038/s41591-019-0422-6

Maru Y, Tanaka N, Itami M, Hippo Y. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors // Gynecol Oncol. 2019;154(1):189–198. https: // doi: 10.1016/j.ygyno.2019.05.005

Lengyel E, Burdette JE, Kenny HA et al. Epithelial Ovarian Cancer Experimental Models // Oncogene. 2014;33(28):3619–3633. https: // doi: 10.1038/onc.2013.321